Stefano Portolano is the founder of Azafaros. Azafaros has raised $150M in total funding. Latest round: Series B. Based in Basel, Switzerland.
Stefano Portolano, MD, is the Chief Executive Officer of Azafaros, a clinical-stage biotechnology company founded in 2018 focused on developing small-molecule treatments for rare lysosomal storage disorders. He joined Azafaros in June 2021 and has led the company through major milestones, including raising a rare ~$150M Series B round in Europe and launching two global Phase 3 trials.
Full founder directory · Investor directory · Company funding database · Fundraising library